In a study just published in Nature Nanotechnology led by Prof. Helena F. Florindo, from the Faculty of Pharmacy, University of Lisbon, and Prof. Ronit Satchi-Fainaro, from the Sackler Faculty of Medicine, Tel Aviv University, describe that the combination of these nanovaccines with therapies available in the clinic. These nanovaccines re-educated host immune system, enabling the identification of protein markers expressed at the surface of tumors, specifically melanoma, which resulted in a remarkable tumor inhibition and prolonged survival in preclinical models of this disease.